Evidence map›Paper›PMID 32297303›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2020

CircRNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145.

Han Yang, Mengjing Zhao, Lihao Zhao, Ping Li, Yuxia Duan, Gang Li

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Potential role ofBiochemistry and biophysics reports · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Han YangDepartment of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Mengjing ZhaoDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, South Bai-xiang street, Ouhai District, Wenzhou, 325000, Zhejiang, China.
Lihao ZhaoDepartment of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Ping LiDepartment of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China. drlipingkuns@163.com.
Yuxia DuanDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, South Bai-xiang street, Ouhai District, Wenzhou, 325000, Zhejiang, China. wydyx59@163.com.
Gang LiDepartment of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. andrewlee0923@wzhospital.cn.
Wenzhou Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNFirst People's Hospital of Kunshan · CN

Funding

Wenzhou Municipal Science and Technology Bureau Y20180213
6 · The paper itself

Abstract

purposeNon-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality world-wide. Recently, a number of circular RNAs (circRNAs) has been found to be differentially expressed in human NSCLCs, correlating with clinico-pathological features. As yet, the expression and potential role of circRNA BIRC6 (circBIRC6) in NSCLC have not been studied.

methodsExpression of circBIRC6 and its target microRNA-145 (miR-145) in human NSCLC cells and tissues was assessed using qRT-PCR. In vitro genetic strategies were used to exogenously alter circBIRC6 and miR-145 expression. Their impact on in vitro and in vivo NSCLC cell behavior was studied.

resultsWe found that circBIRC6 was upregulated in primary human NSCLC tissues and NSCLC cells, whereas its potential target, miR-145, was downregulated. In A549 NSCLC cells and primary human NSCLC cells, shRNA-induced silencing of circBIRC6 potently inhibited their growth, proliferation, migration and invasion. Conversely, we found that exogenous overexpression of circBIRC6 promoted these characteristics. Using RNA immunoprecipitation (RIP) in A549 cells, we found that Argonaute 2 (Ago2) immunoprecipitated together with both circBIRC6 and miR-145. Additional studies revealed that the miR-145 level increased after circBIRC6 silencing in A549 cells, but decreased after circBIRC6 overexpression. Of note, we found that the circBIRC6 silencing-induced anti-A549 activity could be attenuated by a miR-145 inhibitor. Lastly, we found that circBIRC6 silencing inhibited the growth of NSCLC xenografts in severe combined immunodeficient mice.

conclusionsFrom our data we conclude that circBIRC6 overexpression promotes NSCLC cell progression, possibly by sponging miR-145.

Indexed as

Disease ProgressionA549 CellsAnimalsCarcinoma, Non-Small-Cell LungCell ProliferationGene Expression Regulation, NeoplasticGene SilencingHumansLung NeoplasmsMaleMice, SCIDMicroRNAsMiddle AgedRNA, CircularUp-RegulationXenograft Model Antitumor AssaysMicroRNAsMIRN145 microRNA, humanRNA, CircularcircBIRC6miR-145Non-small cell lung cancer (NSCLC)Tumor progression

Identifiers

PMID32297303
PMCPMC12990671
OpenAlexW3016469460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.